在认知障碍和冷漠之前的皮层骨干退化:尸检案例报告
Shoma Hirose1,2, Ryota Kobayashi3, Shigeki Hatakeyama1
1Department of Psychiatry Sunagawa City Medical Center Sunagawa Japan.
PCN reports : psychiatry and clinical neurosciences
|August 4, 2025
概括
皮层骨干退化 (CBD) 最初可能会出现认知问题,掩盖运动症状. 尸检证实CBD在一个病人,其病理与早期的认知衰退和后来的额外金字塔症状相关.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 临床神经学 临床神经学
背景情况:
- 皮层骨干退化 (CBD) 呈现出多种不同的临床表现,使诊断复杂化.
- 这个案例突出了一个尸检确认的CBD患者,最初呈现出认知障碍和冷漠,缺乏运动症状.
研究的目的:
- 报告一个尸检确认的CBD患者的临床过程.
- 为了说明非典型的CBD呈现所带来的诊断挑战.
主要方法:
- 一个51岁的男性患者的详细临床病例介绍.
- 神经成像 (MRI,脑输液,DAT成像) 和神经病理学检查.
主要成果:
- 最初的表现包括认知障碍 (失忆症,执行功能障碍) 和额叶功能障碍.
- 运动症状的发展 (跌倒,额外金字塔体征) 发生在晚些时候.
- 神经病理学揭示了前额叶和基底腺中丰富的tau病理,与临床进展相关.
结论:
- 在CBD中,额叶病理可以表现为早期的认知缺陷.
- 基底腺的tau病理与以后的额外体症状和减少多巴胺载体的可用性相关.
- 临床医生应该考虑在患有痴呆症候群的患者中使用CBD,即使没有初始运动症状.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


